Plasma phosphorylated tau181 outperforms [¹⁸F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease.

ABSTRACT:

Background and purpose

This study was undertaken to compare the performance of plasma p-tau181 with that of [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the identification of early biological Alzheimer disease (AD).

Methods

We included 533 cognitively impaired participants from the Alzheimer's Disease Neuroimaging Initiative. Participants underwent PET scans, biofluid collection, and cognitive tests. Receiver operating characteristic analyses were used to determine the diagnostic accuracy of plasma p-tau181 and [¹⁸F]FDG-PET using clinical diagnosis and core AD biomarkers ([¹⁸F]florbetapir-PET and cerebrospinal fluid [CSF] p-tau181) as reference standards. Differences in the diagnostic accuracy between plasma p-tau181 an

SUBMITTER: Quispialaya KM 

PROVIDER: S-EPMC11555153 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature